Tradestie Institutional Equity Comparison Engine · Market Close Nov 20, 2026

MRNA vs VOR: Which Stock Is the Better Buy Now?

Deterministic 6-pillar institutional evaluation across valuation multiples, TTM & multi-year operating margins, cash generation, options IV skew, and supply-chain moat.

VOR Wins Head-to-Head Institutional Verdict (3–3 across 6 Pillars · 5–5 Matrix Metrics)

VOR Overall Winner 6-Pillar Tally: MRNA 3 – 3 VOR Matrix Metrics: MRNA 5 – 5 VOR

As of Nov 20, 2026, Vor Biopharma Inc. (VOR) is the stronger overall head-to-head candidate over Moderna, Inc. (MRNA) in the Tradestie Institutional Equity Comparison Engine, winning 5–5 core matrix metrics and 3–3 across our 6-pillar institutional scorecard (led by Profitability & Quality, Balance Sheet & Cash Flow, Options & Positioning). MRNA carries a Unified Composite Score of 40.3/100 (SELL) at $195.00 (23.0x Forward P/E, -80.8% operating margin), whereas VOR carries 62.7/100 (BUY) at $19.19 (N/M Forward P/E, 0.0% operating margin).

  • Growth vs. Quality Trade-Off: VOR earns the overall head-to-head edge with a stronger Unified Composite Score (62.7/100 BUY vs. MRNA 40.3/100 SELL) and 1.61β · 62% Vol risk profile, whereas MRNA leads top-line expansion (+29.2% YoY revenue growth, N/M PEG, and 3 of 6 institutional pillars) for higher-beta growth mandates.
  • Technical & Structure Timing Caution: MRNA trades in a Neutral technical trend (CONSOLIDATION options phase, RSI 41.5); meanwhile VOR is in a Weinstein Distribution regime near a flattening 50-day moving average (RSI 49.3). Short-term Markdown, Distribution, or Breakdown phases signal active supply overhead rather than bullish technical support — disciplined entries typically wait for price to reclaim the 20/50-day moving average.

Executive Snapshot Side-by-Side Composite Ratings & Technical Regime

Ask Alpha AI About MRNA vs VOR
MRNA NASDAQ
Moderna, Inc. Common Stock
Biological Products, (No Disgnostic Substances)
$195.00
-2.17% 1D
Market Cap $80.7B
TTM Revenue $2.52B
Forward P/E 23.0x
Beta / 30D Vol 2.23β · 78% Vol
Unified Composite Score
40.3 / 100 SELL
Tech 18.0 Fund 42.0 Flow 67.0 Mom 46.0
Weinstein Technical Phase Neutral · Hold
Mixed signals - no dominant trend phase, RSI 41
RSI-14: 41.5 · SMA20: $225.26 · SMA50: $207.89
VOR NASDAQ Head-to-Head Winner
Vor Biopharma Inc. Common Stock
Biological Products, (No Disgnostic Substances)
$19.19
+3.62% 1D
Market Cap $1.1B
TTM Revenue N/A
Forward P/E N/M
Beta / 30D Vol 1.61β · 62% Vol
Unified Composite Score
62.7 / 100 BUY
Tech 68.0 Fund 64.0 Flow 68.0 Mom 54.0
Weinstein Technical Phase Distribution · Trim / tighten stop
Price near a flattening SMA50 (slope -7.6%) with fading momentum, RSI 49
RSI-14: 49.3 · SMA20: $19.40 · SMA50: $19.48

6-Pillar Scorecard Institutional Category Breakdown (MRNA 3 – 3 VOR)

Columns: Metric · MRNA · VOR
1. Valuation Multiples MRNA
Forward P/E 23.0x N/M
Trailing P/E 23.0x 0.1x
PEG Ratio N/M N/M
EV / Revenue 33.1x N/M
2. Growth & Scale MRNA
Revenue Growth (YoY) +29.2% +0.0%
Earnings Growth (YoY) -85.1% +0.0%
TTM Revenue (USD) $2.52B N/A
Market Cap $80.7B $1.1B
3. Profitability & Quality VOR
Gross Margin -42.0% N/A
Operating Margin -80.8% 0.0%
Net Profit Margin -110.5% 0.0%
Return on Equity (ROE) -34.5% -125.4%
4. Balance Sheet & Cash Flow VOR
Cash Generation (TTM) -$2.04B -$1.63B
Cash Flow Margin -81.0% N/A
Net Cash / Leverage $3.03B Net Debt (0.62x D/E) $1.04B Net Cash
Dividend Yield None (0.00%) None (0.00%)
5. Options & Positioning VOR
Options Structure Phase CONSOLIDATION CONSOLIDATION
Current IV / %ile 89.6% (52nd %ile) 120.9% (6th %ile)
Put/Call OI Skew 1.05x (Balanced) N/A
OBV Trend / Tech Phase DISTRIBUTION · Neutral NEUTRAL · Distribution
6. R&D & Supply-Chain Moat MRNA
OpEx & R&D Intensity 38.8% of Rev ($980M) N/A
90D R&D Disclosures 0 papers 0 papers
Competitive Moat Cyclical / Execution-Driven Positioning Cyclical / Execution-Driven Positioning
Supply-Chain Role Biotechnology Operator Biotechnology Operator

Core Matrix Head-to-Head Valuation, Margin, Cash Flow & Risk Table

Core Matrix Wins: MRNA (5) vs VOR (5)
Institutional Metric MRNA VOR Criterion Row Edge
Market Capitalization
Scale
$80.7B $1.1B Larger Scale MRNA
Trailing P/E Ratio
Valuation
23.0x 0.1x Lower Multiple VOR
Forward P/E Ratio
Valuation
23.0x N/M Lower Multiple MRNA
Revenue Growth (YoY)
Growth
+29.2% +0.0% Higher Growth MRNA
Operating Margin (TTM)
Profitability
-80.8% 0.0% Higher Margin VOR
Net Profit Margin
Profitability
-110.5% 0.0% Higher Margin VOR
Return on Equity (ROE)
Capital Efficiency
-34.5% -125.4% Higher ROE MRNA
52-Week Range Position
Momentum
67% ($22–$281) 65% ($6–$26) Stronger Trend MRNA
Beta / 30D Volatility
Risk Regime
2.23β · 78% Vol 1.61β · 62% Vol Lower Realized Risk VOR
Unified Institutional Score
Composite Signal
40.3 / 100 (SELL) 62.7 / 100 (BUY) Higher Composite VOR
Trailing 12M Revenue (USD)
Operating Scale
$2.52B N/A FX-Normalized USD Scale
Gross Profit Margin (TTM)
Unit Pricing Power
-42.0% N/A Higher Margin Quality
PEG Ratio & EV / Revenue
Growth-Adjusted Valuation
N/M PEG · 33.1x EV/Rev N/M PEG · N/M EV/Rev Lower Multiple Valuation
Cash Flow & Balance Sheet
Capital Self-Funding
-$2.04B ($3.03B Net Debt (0.62x D/E)) -$1.63B ($1.04B Net Cash) Higher Cash / Net Cash Solvency

Momentum Normalized Relative Price Performance (1M · 3M · 6M · 1Y)

1M Horizon VOR +5.09 pp
MRNA: -3.77% · VOR: +1.32%
3M Horizon MRNA +55.9 pp
MRNA: +40.4% · VOR: -15.5%
6M Horizon MRNA +282.05 pp
MRNA: +315.96% · VOR: +33.91%
1Y Horizon MRNA +561.05 pp
MRNA: +706.45% · VOR: +145.4%

Financial Trajectory Operating Profitability Benchmark (Trailing 12-Month)

Split-Invariant USD Revenue & Operating Margin (%)

Standardized multi-year USD domestic revenue schedules are unavailable for foreign-domiciled ADR filing schedules on MRNA vs VOR. Trailing 12-month operating profitability (MRNA -80.8% vs VOR 0.0%) and valuation multiples (MRNA 23.0x vs VOR N/M Forward P/E) are benchmarked directly in Pillar 4 below.

MRNA ADR TTM Benchmark FX-Normalized USD
TTM Revenue$2.52B
Gross Margin-42.0%
Op. Margin-80.8%
ROE / Fwd P/E-34.5% · 23.0x
VOR ADR TTM Benchmark FX-Normalized USD
TTM RevenueN/A
Gross MarginN/A
Op. Margin0.0%
ROE / Fwd P/E-125.4% · N/M

Options Positioning Implied Volatility, Put/Call Skew & Dealer Gamma Corridor

Live Options Phase Tracker
MRNA CONSOLIDATION
22d in phase · OBV DISTRIBUTION
Current IV 89.6%
IV Percentile 52nd %ile
Put/Call OI Skew 1.05x (Balanced)
IV Regime Balanced (25th–60th %ile)
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
Net Delta Signal NEUTRAL
OBV Flow DISTRIBUTION
Exact MRNA Put/Call Gamma Wall strikes & dealer pinning corridor require Tradestie Pro. Unlock 14-Day Free Trial →
VOR CONSOLIDATION
56d in phase · OBV NEUTRAL
Current IV 120.9%
IV Percentile 6th %ile
Put/Call OI Skew N/A
IV Regime Compressed (<25th %ile)
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
Net Delta Signal BULLISH
OBV Flow NEUTRAL
Exact VOR Put/Call Gamma Wall strikes & dealer pinning corridor require Tradestie Pro. Unlock 14-Day Free Trial →
LIVE OPTIONS CHAIN · T+5 TRADING DAY HORIZON Spot $215.27 · IV 83.7%

MRNA Simulated 5-Day Option Payoffs vs. Owning 100 Shares ($21,527)

Compare $21,527 in 100-share capital outlay against risk-defined 5-day vertical spreads, put-wall income, and 3-leg structures at 83.7% ATM IV.

5-DAY BULLISH SWING Liq A

Dec 18 $220 / $260 Bull Call Spread

Buy 1x $220C · Sell 1x $260C · 32d

Net Entry $1,105 Debit
T+5d @ +5% Move +$267 (+24%)
Max Risk / Buffer $1,105 Capped
5d Edge & Liquidity 0.7x R:R · Liq A
Simulate 5-Day Payoff →
PUT-WALL MONTHLY INCOME Liq A

Dec 18 $190 / $180 Bull Put Spread

Sell 1x $190P · Buy 1x $180P · 32d

Net Entry $255 Credit
Max Credit / Yield +$255 (+34.2% RoM)
Max Risk / Buffer -12.9% Cushion ($745 Mgn)
5d Edge & Liquidity 74% PoP · Liq A
Simulate 5-Day Payoff →
ASYMMETRIC 3-LEG STRUCTURE Liq A

Dec 18 $190P / $220-$260C Seagull

Sell 1x $190P · Buy 1x $220/$260C · 32d

Net Entry $140 Debit
T+5d @ +5% Move +$693 (+23.1% RoM)
Max Risk / Buffer -11.7% Put Cushion ($3,005 Mgn)
5d Edge & Liquidity 1.1x R:R · Liq A
Simulate 5-Day Payoff →

Simulated T+5 trading day payoffs use live option midpoints, bid-ask spread adjustments, and implied volatility skew for educational scenario modeling only — not personalized investment advice. Options involve substantial risk.

Moat & R&D Supply-Chain Positioning, Bottleneck Moat & R&D Velocity

Corporate R&D & Foundry Leaderboard
MRNA Moat Profile Cyclical / Execution-Driven Positioning
Biotechnology Operator
Competes within the Biotechnology value chain with $80.7B market capitalization and -80.8% operating margin.
OpEx & R&D Reinvestment 38.8% of Rev ($980M)
90D Engineering Disclosures 0 Published · mRNA Therapeutics
VOR Moat Profile Cyclical / Execution-Driven Positioning
Biotechnology Operator
Competes within the Biotechnology value chain with $1.1B market capitalization and 0.0% operating margin.
OpEx & R&D Reinvestment N/A
90D Engineering Disclosures 0 Published

Investor FAQ MRNA vs VOR Key Questions & Quantitative Answers

As of Nov 20, 2026, Vor Biopharma Inc. (VOR) is the stronger overall head-to-head candidate over Moderna, Inc. (MRNA) in the Tradestie Institutional Equity Comparison Engine, winning 5–5 core matrix metrics and 3–3 across our 6-pillar institutional scorecard (led by Profitability & Quality, Balance Sheet & Cash Flow, Options & Positioning). MRNA carries a Unified Composite Score of 40.3/100 (SELL) at $195.00 (23.0x Forward P/E, -80.8% operating margin), whereas VOR carries 62.7/100 (BUY) at $19.19 (N/M Forward P/E, 0.0% operating margin). Growth vs. Quality Trade-Off: VOR earns the overall head-to-head edge with a stronger Unified Composite Score (62.7/100 BUY vs. MRNA 40.3/100 SELL) and 1.61β · 62% Vol risk profile, whereas MRNA leads top-line expansion (+29.2% YoY revenue growth, N/M PEG, and 3 of 6 institutional pillars) for higher-beta growth mandates. Technical & Structure Timing Caution: MRNA trades in a Neutral technical trend (CONSOLIDATION options phase, RSI 41.5); meanwhile VOR is in a Weinstein Distribution regime near a flattening 50-day moving average (RSI 49.3). Short-term Markdown, Distribution, or Breakdown phases signal active supply overhead rather than bullish technical support — disciplined entries typically wait for price to reclaim the 20/50-day moving average.

MRNA leads the Growth & Scale pillar: MRNA posts +29.2% YoY revenue growth and -85.1% YoY earnings growth on $2.52B TTM revenue (-42.0% gross margin, -80.8% operating margin), compared with VOR at +0.0% YoY revenue growth and +0.0% YoY earnings growth on N/A TTM revenue (N/A gross margin, 0.0% operating margin). On trailing 12-month operating scale, MRNA generates $2.52B in USD-normalized revenue versus N/A for VOR. In operating R&D and SG&A reinvestment, MRNA deploys 38.8% of Rev ($980M) (0 90-day corporate R&D disclosures) versus N/A (0 disclosures) for VOR.

MRNA screens cheaper on headline valuation multiples. MRNA trades at 23.0x Forward P/E, 23.0x Trailing P/E, N/M PEG, and 33.1x EV/Revenue (-81.0% FCF margin), whereas VOR trades at N/M Forward P/E, 0.1x Trailing P/E, N/M PEG, and N/M EV/Revenue (unreported FCF margin). Multiples above 150x or negative earnings denominators are marked N/M to avoid distorted accounting comparisons; weigh lower Forward P/E and PEG against MRNA (-34.5% ROE) versus VOR (-125.4% ROE) capital efficiency.

In options market volatility and institutional positioning, MRNA carries 89.6% implied volatility (52nd %ile, Balanced (25th–60th %ile)), a 1.05x (Balanced) Put/Call open-interest ratio, DISTRIBUTION on-balance volume, and sits in a CONSOLIDATION options structure phase (2.23β · 78% Vol realized risk). By comparison, VOR carries 120.9% implied volatility (6th %ile, Compressed (<25th %ile)), unclassified Put/Call open interest, NEUTRAL on-balance volume, and sits in a CONSOLIDATION options structure phase (1.61β · 62% Vol realized risk).

Cross-Compare 1-Click Peer Rivalries & Single-Stock Research

Launch Custom Ticker Comparison →

Powered by Tradestie Institutional Equity Comparison Engine & standardized corporate financial telemetry. Market close as of Nov 20, 2026. For educational research only; not investment advice.